The missing link in Bangladesh’s innovation economy
Why translating promising research into investable companies requires its own institutions, capabilities, and disciplined decisions.
Read articleWriting & publications
Ideas, evidence,
and judgment.
Essays, published perspectives, and scientific papers on the decisions that shape companies, medicines, and institutions.
Featured in The Daily Star · Slow Reads
The missing link in Bangladesh’s innovation economy
How should promising research become a business? This essay examines the decisions between discovery and commercialisation: licensing, partnerships, further development, company formation, and knowing when to stop.
Read the essay28 works
Buying Evidence You Cannot Use
Capital allocation should preserve the ability to act on new evidence. A practical examination of commitments, uncertainty, and the options that remain after an experiment.
Read articleBangladesh’s Next Growth Phase Requires a New Operating System
The capabilities that supported manufacturing growth must be complemented by institutions that can fund uncertain outcomes, commercialize knowledge, and reward learning.
Read articleOur Drugs Are Becoming More Precise Than Our Diseases
As therapies become more precise, broad disease definitions can limit development. Patient selection, biomarkers, and biological context belong at the beginning of the program.
Read articleThe New Scarcity
AI can expand the set of credible options faster than an organization can act on them. The scarce resources become judgment, attention, and the capacity to commit.
Read articleMost Strategy Problems Begin Before Strategy
An exploration of the compass, questions, and difficult choices that shape strategy before execution begins.
Read articleAI’s Biggest Prize in Biopharma Is Not Molecule Generation. It Is Better Judgement.
A perspective on AI in biopharma and the quality of portfolio decisions.
Read articleVenture Capital Is Not Just Funding; It Is a Governance System
Venture capital, corporate governance, and the decisions that shape young companies.
Read articleSilicon Valley’s Biggest Export Isn’t Venture Capital. It Is a Theory of Uncertainty.
How organizations make commitments when the probabilities cannot be known in advance.
Read articleGetting to Failure Faster Isn’t the Same as Getting to Medicines Faster
Where AI is strongest today—and where the next bottlenecks in drug development are emerging.
Read articleYour Biopharma Has a Data Lake. It Doesn’t Have a Memory of Why It Decided Anything.
Why storing evidence is not enough: organizations also need to preserve the assumptions, disagreements, and judgment behind decisions.
Read articleBeyond the Headlines: Reading Between the Lines of Biopharma’s 2025
Part of Biopharma’s 2025 Reset: market signals, changing investor expectations, and the return of strategic discipline.
Read articleBiopharma’s Reawakening: How 2025’s M&A Cycle Reshapes JPM
Part of Biopharma’s 2025 Reset: how capital, consolidation, and therapeutic focus are reshaping the biotech landscape.
Read articleFDA’s NAMs Initiative: A Strategic Inflection Point
Part of Human-Relevant Biology as Biotech Strategy: new approach methodologies and their implications for translational risk.
Read articleThe MOAT That Wins: Why Human Biology Decides the Future of Biotech
Why platforms grounded in human biology may become stronger competitive moats.
Read articleNew Approach Methods (NAMs): The $15 Billion Drug Development Problem
The economic burden of failed translation and the role of human-relevant models in development strategy.
Read articleThe $2.6 Billion Innovation Trap: Reengineering Finance for Drug Development
Why drug development’s cost problem cannot be solved by science alone, and why financing models, portfolio discipline, and capital allocation matter.
Read articleThe Dual Mandate: Profit & Public Good in Pharmaceutical Corporations
How pharmaceutical companies balance therapeutic impact, commercial sustainability, and public trust.
Read articleFrom Genetic Ambiguity to Functional Clarity: The Clinical Rise of Mass Spectrometry
Functional proteomics as a bridge between molecular signals and clinical confidence in rare disease diagnosis.
Read articleWhat the FDA’s 2025 Approvals Signal for Biotech Portfolios in 2026
A strategic readout of clearer biology, evidence readiness, rare disease momentum, small-molecule resilience, and disciplined development strategy.
Read articleTackling the challenges of new approach methods for predicting drug effects from model systems
How iPSC-derived models, microphysiological systems, and computational tools may improve prediction of human drug safety and efficacy—and the remaining challenges of scalability, standardization, reproducibility, and genetic diversity.
Read paperFDA Modernization Act 2.0 Paves the Way to Computational Biology and Clinical Trials in a Dish
A perspective on the emerging role of human cell models, organoids, microphysiological systems, AI, and computational biology in making preclinical development more clinically predictive.
Read paperMutations in the exocyst component EXOC2 cause severe defects in human brain development
Patient genetics and cellular studies connect EXOC2 dysfunction, impaired exocytosis, and disrupted cilia localization to severe neurodevelopmental disease.
Read paperExocyst dynamics during vesicle tethering and fusion
CRISPR/Cas9, high-speed TIRF microscopy, proteomics, and single-molecule imaging reveal how the mammalian exocyst assembles and functions as a dynamic two-part complex.
Read paperThe Par3 polarity protein is an exocyst receptor essential for mammary cell survival
How Par3 recruits the exocyst near tight junctions, enabling basolateral protein delivery, maintaining PI3K–Akt survival signaling, and preventing apoptosis.
Read paperEpithelial Homeostasis
A review of mechanisms that maintain epithelial integrity, architecture, and function, including mechanical sensing, YAP/TAZ signaling, cell extrusion, and cell competition.
Read paperKIF14 negatively regulates Rap1a–Radil signaling during breast cancer progression
How KIF14 tethers Radil to microtubules to regulate integrin activation and cell adhesion, and the role of Radil in migration, invasion, and metastasis.
Read paperG Protein βγ Subunits Regulate Cell Adhesion through Rap1a and Its Effector Radil
A signaling mechanism connecting GPCR activation with cell–matrix adhesion through Gβγ, Rap1a, and Radil.
Read paperNo works match that search. Try a different title or subject.